Table 2 Risk factors for anthracycline cardiotoxicity
Risk factorAspectsReferences
Cumulative anthracycline doseCumulative doses >500 mg/m2 associated with significantly elevated long term riskLipshultz et al 19915; Krischer et al 199712; Lipshultz et al 19956; Lipshultz et al 20057
Length of post-therapy intervalIncidence of clinically significant cardiotoxicity increases progressively post-therapyLipshultz et al 19915; Lipshultz et al 19956; Lipshultz et al 20057
Rate of anthracycline administrationProlonged administration to minimise circulating dose volume may decrease toxicity; results are mixedLipshultz et al 200223
Individual anthracycline doseHigher individual anthracycline doses are associated with increased late cardiotoxicity, even when cumulative doses are limitedLipshultz et al 19956; Lipshultz et al 20057
Type of anthracyclineLiposomal encapsulated preparations may reduce cardiotoxicity. Conflicting data exist about anthracycline analogues and cardiotoxicity differencesWouters et al 200514; Barry et al 200711; Van Dalen et al 200620
Radiation therapyCumulative radiation dose >30 Gy; prior or concomitant anthracycline treatmentGiantris et al 19989; Adams et al 200515
Concomitant therapyTrastuzumab, cyclophosphamide, bleomycin, vincristine, amsacrine, and mitoxantrone may increase susceptibility/toxicity. Others are implicated as wellGiantris et al 19989; Barry et al 200711
Pre-existing cardiac risk factorsHypertension; ischaemic, myocardial, and valvular heart disease; prior cardiotoxic treatmentBarry et al 200711
ComorbiditiesDiabetes, obesity, renal dysfunction, pulmonary disease, endocrinopathies, electrolyte and metabolic abnormalities, sepsis, infection, pregnancyBarry et al 200711
AgeBoth young and advanced age at treatment are associated with elevated riskLipshultz et al 19915; Lipshultz et al 19956
SexFemales are at greater risk than malesLipshultz et al 19956
Additional factorsTrisomy 21; African American ancestryKrischer et al 199712